In silico development of new candidate of NADPH oxidase inhibitor for hypertension treatment

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Hypertension is a silent killer that becomes the important risk factor for stroke and ischemic heart disease. Oxidative stress which results from high production of reactive oxygen species (ROS) in the endothelial layer, contributes to hypertension pathophysiology. The high activity of NADPH oxidase is the main ROS source. Many medicinal plants have been developed to treat some human diseases. This study aimed to explore virtually Indonesian phytochemicals as a NADPH oxidase inhibitor for hypertension treatment. This bioinformatics study used a molecular docking method with P47-phox protein and apocynin as protein target and standard ligand respectively, which were obtained from Protein Data Bank and ZINC databases with 1NG2 and 0162515 codes. Indonesian phytochemicals were obtained from the HerbalIBD, had molecular structure from the PubChem database, and met the Lipinski's criteria. The AutoDock Vina version 1.1.2 was used to analyse the binding affinity and sites and the PyMol 1.3 program was for visualization of molecular docking results. Apocynin interacted with P47-phox with -5.5 kcal/mol binding score and binding at Asp221, Arg302, Arg316 residues to prevent NADPH activation. Compared to apocynin, morindone had lower binding score (-7.7 kcal/mol) to bind to P47-phox and had similar binding sites at Arg 302, Arg 316, and Arg 318 residues. In conclusion, morindone potentially becomes a NADPH oxidase inhibitor in silico for hypertension treatment.

References Powered by Scopus

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

10527Citations
N/AReaders
Get full text

ACRP30/adiponectin: An adipokine regulating glucose and lipid metabolism

1114Citations
N/AReaders
Get full text

Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant

646Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antioxidant enzymes and vascular diseases

6Citations
N/AReaders
Get full text

In Silico Analysis of Antioxidant Phytochemicals with Potential NADPH Oxidase Inhibitory Effect

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Laksono, A. B., Kusumawati, R., Suselo, Y. H., & Indarto, D. (2021). In silico development of new candidate of NADPH oxidase inhibitor for hypertension treatment. In IOP Conference Series: Earth and Environmental Science (Vol. 819). IOP Publishing Ltd. https://doi.org/10.1088/1755-1315/819/1/012071

Readers' Discipline

Tooltip

Pharmacology, Toxicology and Pharmaceut... 1

100%

Save time finding and organizing research with Mendeley

Sign up for free